Search Results
Your search for ASCO matches 20854 pages
Showing 4951 - 5000Public Comment on National Coverage Analysis of Screening for Lung Cancer With Low-Dose Computed Tomography
The following letter is adapted from comments made to the Centers for Medicare and Medicaid Services (CMS) by the American College of Radiology, the GO2 Foundation for Lung Cancer, and the Society of Thoracic Surgeons. “The American College of Radiology, the GO2 Foundation for Lung Cancer, and the...
I’m Alive by Sheer Force of Will—and a Lot of Luck
From the moment I felt a searing pain go through my right breast, I had a premonition that something was very wrong. Although I couldn’t feel anything unusual when I did a breast self-exam, I made an appointment with my gynecologist for a more thorough clinical breast exam and a mammogram. Because...
The Compelling Story of Cystic Fibrosis and the Dawn of Precision Medicine
Woe to the child who tastes salty from a kiss on the brow” was a forbidding prophecy from Medieval Europe, presaging unknown disease. Today, we know that salty skin is a telltale sign of cystic fibrosis in children, a disease that eluded medical identification until 1938, when an American...
Bone-Protecting Agents Shown to Reduce Fracture Rate in Men With Metastatic Prostate Cancer
Prostate cancer experts have often stated it is important to add a bone-protecting agent for patients on treatment for metastatic castration-resistant prostate cancer. Recent evidence in support of this recommendation comes from a study presented during the 2021 ASCO Annual Meeting, confirming a...
Small Study Suggests ALK Targeting May Be of Benefit in Adult Neuroblastoma
Targeting mutations appears to be bearing fruit in the treatment of some difficult-to-treat tumors. For instance, in one study of adult-onset neuroblastoma, targeting ALK mutations in ALK-positive tumors demonstrated activity, even in patients who had not responded to their first ALK inhibitor. Of...
Memorial Sloan Kettering Announces New Initiative to Focus on Lung Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) recently announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of new therapies to treat this disease. Lung cancer is responsible for 25% of all cancer deaths and is the leading...
American Ginseng
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Eugenie Spiguel, MSN, ANP-BC, and Jyothirmai Gubili, MS, focus on American...
Canadian Oncologists Report Costly Delays in Their Drug Regulatory Process
Canada’s publicly funded health-care system has a complex drug approval and funding process. Due to multiple assessment steps and bureaucratic processes, newly developed cancer drugs can often experience long delays before oncologists may use them to treat their patients with cancer. Several...
Expert Point of View: Amit M. Oza, MD, MBBS
Invited discussant of the FORWARD II trial,1Amit M. Oza, MD, MBBS, concluded that bevacizumab and mirvetuximab soravtansine was a “very well tolerated and effective” combination with “encouraging activity,” even in patients previously treated with bevacizumab and weekly paclitaxel. Dr. Oza is Head ...
B-Cell Acute Lymphoblastic Leukemia: Update on Clinical Trials
“Learning never exhausts the mind.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on treatments under study ...
Early-Phase Trial Finds Mirvetuximab Soravtansine Plus Bevacizumab Active in Recurrent Ovarian Cancer
In patients with recurrent ovarian cancer, the antibody-drug conjugate mirvetuximab soravtansine, given with bevacizumab, showed antitumor activity leading to durable responses in platinum-agnostic patients with strong expression of folate receptor alpha (FRα), researchers reported at the 2021 ASCO ...
UCSF Names Ajay Maker, MD, FACS, Chief of Surgical Oncology
Ajay Maker, MD, FACS, has been appointed Chief of the new Division of Surgical Oncology in the Department of Surgery and the Maurice Galante Distinguished Professor in Surgical Oncology at the University of California, San Francisco (UCSF). He will lead surgical oncology services—including breast,...
Expert Point of View: Kostas Stamatopoulos, MD, PhD
In the phase III GLOW trial, the all-oral regimen of fixed-duration ibrutinib plus venetoclax as first-line treatment for older or unfit patients with chronic lymphocytic leukemia (CLL) showed superior efficacy compared with chlorambucil and obinutuzumab.1Kostas Stamatopoulos, MD, PhD, of the...
Sukhmani K. Padda, MD, to Direct Thoracic Medical Oncology at Cedars-Sinai Cancer Center
Thoracic medical oncologist Sukhmani K. Padda, MD, was recently selected to direct Thoracic Medical Oncology at Cedars-Sinai Cancer Center in Los Angeles. Dr. Padda’s appointment, following a national search, reflects her breadth of experience as a clinician and researcher in the field of thoracic...
Bringing Palliative Care to Native American Patients With Cancer
Native Americans are among the most underserved minority populations in the United States and are disproportionately affected by cancer. They have the lowest survival rates for nearly all types of cancer of any minority population and much higher rates of certain types of cancer, including lung,...
Phase III GLOW Trial: Improved Outcomes With First-Line Ibrutinib Plus Venetoclax in Elderly Patients With CLL
Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior outcomes compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL), based on the primary analysis of the phase III GLOW trial presented during the European Hematology...
Oncology Community Mourns the Loss of Investigator Angelo Di Leo, MD, PhD
Oncologist Angelo Di Leo, MD, PhD, recently died after a long struggle with neurodegenerative disease. He was 58 years old. Dr. Di Leo was devoted to breast cancer research for more than 25 years. He first trained with Gianni Bonadonna, MD, in Milan, followed by postdoctoral research at Jules...
Bridging the Gender Gap in Oncology
Women account for a growing proportion of the oncology workforce. Multiple studies, however, show that women oncologists are underrepresented in leadership positions, may have significantly lower salaries than men, and may be subjected to discriminatory practices stimulated by a medical culture...
Expert Point of View: Philip McCarthy, MD
Commenting on the updated results of the MAIA trial1 for The ASCO Post was Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York. Dr. McCarthy described how the...
Role of PI3K Inhibition in Indolent Lymphomas
As reported by Fowler et al in the Journal of Clinical Oncology1—and summarized in this issue of The ASCO Post—the international phase IIb UNITY-NHL trial of 208 patients with marginal zone lymphoma (MZL; n = 69), follicular lymphoma (FL; n = 117), and small lymphocytic lymphoma (SLL; n = 22)...
MAIA Update: Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma
In an updated analysis of the phase III MAIA trial, the addition of the monoclonal antibody daratumumab to the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone (D-Rd) significantly improved overall survival over lenalidomide/dexamethasone alone in patients newly diagnosed...
Factoring Fertility Preservation Into Breast Cancer Treatment
Breast cancer is the most commonly diagnosed cancer in women of reproductive age. Approximately 10% of breast cancers are diagnosed in this age group.1 Young age at diagnosis is an adverse prognostic factor, and most young women will be offered chemotherapy and/or endocrine therapy, both of which ...
FDA Pipeline: Designations for Therapies in Myelodysplastic Syndromes and Triple-Negative Breast Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted special designation status to treatments for myelodysplastic syndromes and advanced triple-negative breast cancer. Breakthrough Therapy Designation for Venetoclax in Combination With Azacitidine for Myelodysplastic Syndromes Venetoclax...
Implementation of a Program Providing Free Cancer Screenings, Same-Day Results
Evidence shows that early detection and treatment of cancer can significantly improve health outcomes. However, women in Mississippi—particularly in underserved populations—experience high rates of late-stage cancer diagnoses. A report published by Michelle Williams, PhD, and colleagues in the...
Outcomes in Patients With HER2-Low–Positive Breast Cancer Participating in Neoadjuvant Clinical Trials
In a pooled analysis of individual patient data from breast cancer neoadjuvant clinical trials reported in The Lancet Oncology, Carsten Denkert, MD, and colleagues found that pathologic complete response and survival rates for patients with HER2-low–positive vs HER2-zero tumors differed according...
Expert Point of View: Carol Aghajanian, MD
“The phase III ENGOT/GCIG study1 proved to be negative, with no advantage seen with the extension of bevacizumab treatment,” said the abstract’s invited discussant, Carol Aghajanian, MD, Chief of the Medical Gynecologic Oncology Service at Memorial Sloan Kettering Cancer Center, New York. Dr....
Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better
In advanced ovarian cancer, the duration of maintenance bevacizumab should remain 15 months, according to the European multicenter phase III ENGOT/GCIG trial. These results were presented during the 2021 ASCO Annual Meeting by Jacobus Pfisterer, MD, PhD, of the AGO Study Group and Gynecologic...
Study Finds the COVID-19 Pandemic Created Significant Disruptions in Cancer Screenings at Federally Qualified Health Centers
A new study has found that the COVID-19 pandemic contributed to significant disruptions in breast, colorectal, and cervical cancer screenings at federally qualified health systems spanning 15 states across the United States. The postponed screenings have created backlogs that systems will need to...
Pembrolizumab/Lenvatinib Granted Regular Approval for Advanced Endometrial Carcinoma
On July 21, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with lenvatinib (Lenvima) for patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR). These patients must have ...
Transvaginal Ultrasound Screening Misses More Cases of Endometrial Cancer in Black Women vs White Women
A screening tool used to evaluate the need for endometrial cancer biopsies in women frequently misses the signs of this cancer in Black women, according to a new study published by Kemi M. Doll, MD, and colleagues in JAMA Oncology. Dr. Doll, a gynecologic oncologist at the University of Washington...
Efficacy of Dendritic Cell Vaccines Plus Standard Therapy for Breast Cancer
A report published by Oba et al in the Journal for ImmunoTherapy of Cancer shares new data on combining standard treatment for breast cancer with a particular form of cancer immunotherapy—dendritic cell vaccines. The study is reportedly the first to demonstrate that in situ dendritic cell vaccines...
Study Identifies MET Amplification as a Driver for Some Non–Small Cell Lung Cancers
A study published by D. Ross Camidge, MD, PhD, and colleagues in the Journal of Thoracic Oncology has helped to define MET amplification as a rare but potentially actionable driver for non–small cell lung cancer (NSCLC). Dr. Camidge said many of the major developments in the treatment of NSCLC have ...
Combination Ficlatuzumab and Cytarabine Show Clinical Activity in Relapsed/Refractory AML
Despite advances in the treatment of acute myeloid leukemia (AML), only 29.5% of patients with the cancer are alive 5 years after diagnosis. Even with aggressive therapy, just 30% of patients achieve a complete remission with a median survival of 7.5 months, making it imperative to develop novel...
Atezolizumab Plus Bevacizumab in Malignant Peritoneal Mesothelioma
A phase II study published by Kanwal Raghav, MBBS, MD, and colleagues in Cancer Discovery found that combination treatment with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab was well tolerated and resulted in a 40% objective response rate in patients with advanced malignant...
Study Estimates Costs Associated With Metastatic Breast Cancer Treatment May Increase Substantially in the Coming Decade
A study from the UNC Center for Health Promotion and Disease Prevention (HPDP) estimates that annual costs associated with metastatic breast cancer treatment among women in the United States will total $152.4 billion in 2030—nearly two and a half times the estimate for 2015 costs—due to an increase ...
FDA Approves Belumosudil for Chronic Graft-vs-Host Disease
On July 16, the U.S. Food and Drug Administration (FDA) approved belumosudil (Rezurock), a kinase inhibitor, for adult and pediatric patients aged 12 years and older with chronic graft-vs-host disease after failure of at least two prior lines of systemic therapy. KD025-213 Efficacy was evaluated in ...
Terry P. Mamounas, MD, MPH, on Breast Cancer: Extended Aromatase Inhibitor Therapy
Terry P. Mamounas, MD, MPH, of the University of Florida Health Cancer Center, discusses results from the NRG Oncology/NSABP B-42 study, which examined the Breast Cancer Index and its ability to predict whether extended treatment with letrozole benefits patients with hormone receptor–positive...
Study Identifies Gut Microbes Associated With Combination Immunotherapy Response and Adverse Events
Researchers have found that specific intestinal microbiota signatures may correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. The study, published by Andrews et al in Nature Medicine, also identified a potential new strategy to treat toxicity—while...
Melinda L. Telli, MD, on Breast Cancer: Neoadjuvant Talazoparib for Early HER2-Negative Disease
Melinda L. Telli, MD, of Stanford University, discusses results of a phase II study on neoadjuvant talazoparib in germline BRCA1/2 mutation–positive, early HER2-negative breast cancer. In this setting, talazoparib monotherapy was active and yielded pathologic complete response rates comparable to...
Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination
In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection against the virus will be...
Study Explores Ketogenic Diet and Intermittent Fasting in Patients With Brain Cancer
More research into the efficacy of a modified ketogenic diet may be beneficial for people with brain tumors, according to a new study published by Schreck et al in the journal Neurology. The diet, which is high in fat and low in carbohydrates, led to changes in the metabolism in the body and the...
Expert Point of View: Jason J. Luke, MD
The invited discussant of LEAP-004, Jason J. Luke, MD, Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center, University of Pittsburgh Hillman Cancer Center, said the investigators of LEAP-0041 deserve credit for designing a study with a clearly defined...
LEAP-004 Trial Update on Lenvatinib Plus Pembrolizumab After Disease Progression in Metastatic Melanoma
Longer follow-up of the LEAP-004 trial in metastatic melanoma upheld the benefit seen with the VEGF kinase inhibitor lenvatinib plus the PD-1 inhibitor pembrolizumab for patients experiencing disease progression on prior checkpoint blockade, investigators reported at the 2021 ASCO Annual Meeting.1 ...
Paul G. Richardson, MD, on Multiple Myeloma and COVID-19: An Update
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses challenges patients with multiple myeloma have faced as a result of the COVID-19 pandemic and the research he and his international colleagues are conducting to better understand these difficulties and improve patient care.
Effect of Obesity on Receipt of Chemotherapy in Patients With Colorectal Cancer
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy relative to their body surface area than nonobese patients, according to results from a large meta-analysis reported by Slawinski et al at the ESMO World Congress on Gastrointestinal Cancer 2021 (Abstract...
ASCO and COA Jointly Release Oncology Medical Home Standards
Today, ASCO and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards, which provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence-based cancer care. These standards, which were published by Woofter et al in JCO Oncology...
Expert Point of View: Thomas Seufferlein, MD, PhD
The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-paclitaxel plus gemcitabine vs gemcitabine alone…. The combination improves long-term survival and...
DESTINY-Gastric01 Exploratory Biomarker Analysis Examines Efficacy of Trastuzumab Deruxtecan-nxki Among Patients With HER2-Positive and HER2-Low Gastric Cancer
Trastuzumab deruxtecan-nxki demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer, according to findings from a post hoc exploratory biomarker analysis presented by Kohei Shitara, MD, and colleagues at the ESMO World ...
APACT: 5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine
Five-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer, according to Margaret A. Tempero, MD, Director of the University of California San Francisco Pancreas Center, who...
Breast Cancer Expert Joseph A. Sparano, MD, FACP, to Join Mount Sinai Health System
Mount Sinai Health System has recruited an internationally recognized expert in the management of breast cancer and human immunodeficiency virus (HIV)-associated malignancies, Joseph A. Sparano, MD, FACP, as Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute...
